Boehringer Ingelheim Pharmaceuticals, Inc. Recalls

1 recall found for Boehringer Ingelheim Pharmaceuticals, Inc. — June 2026.

Medications: 1

The recalls listed below are active notices associated with Boehringer Ingelheim Pharmaceuticals, Inc. in the FDA, NHTSA, USDA, and CPSC databases. None of the current recalls are classified as urgent. Check the specific lot numbers, model numbers, or production date codes in each notice carefully — a recall typically covers specific production runs, not everything a manufacturer sells.

A manufacturer appearing in the recall database does not indicate an ongoing safety failure. High-volume companies with large product lines naturally appear more frequently. What matters is whether your specific product — identified by lot number, model number, or date code — is included in a recall notice.

Browse all medication recalls
NoticeMedications

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per B

Boehringer Ingelheim Pharmaceuticals, Inc.

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

View recall →